市场调查报告书
商品编码
1267471
体外膜氧疗市场——按方式、按应用、按患者人数分类,全球预测,2023-2032 年Extracorporeal Membrane Oxygenation Market - By Modality, By Application, By Patient Population & Global Forecast, 2023 - 2032 |
由于欧洲政府举措和计划的增加,到 2032 年,全球体外膜氧疗 (ECMO) 市场预计将显着增长。
近年来,欧洲的呼吸道和心血管疾病患病率显着上升,预计这一趋势在预测期内将持续下去。 CVD 病例的增加导致政府采取措施和各种计划来提高公众意识。 政府对新兴国家基础设施发展的资助将有助于使昂贵的机器更容易获得,并促进该行业的收入增长。
例如,2021 年 1 月,Braile Biomedica 与 Eldorado Institute 和 Embrapii 合作推出了 SOLIS 系统,这是一款针对 COVID-19 的全国性产品。 ECMO(体外膜氧合),一种体外呼吸,构成了这个系统。 这样的产品介绍使公司能够确保其在市场上的地位。
ECMO 市场根据方法、类型、患者人数和地理位置进行细分。
根据我们的方法,静脉 (VV) 部分在 2022 年持有超过 1.8 亿美元。 静脉 ECMO 设备是一种增加血流量和氧气浓度,同时减轻心臟负担和支持血液动力学的设备。 预计在预测期内,心肺疾病负担的增加将增加对静脉 ECMO 的需求。
从 2023 年到 2032 年,按类型划分,呼吸领域预计将以超过 3% 的复合年增长率增长。 该细分市场增长的一个关键因素是患有各种呼吸系统疾病的人出现呼吸衰竭的风险。 此外,易患呼吸系统疾病的老年人口不断增加,将进一步完善不断增长的市场环境。
根据患者人口统计,成人细分市场预计在整个预测期内将出现积极的市场扩张。 不断增长的老年人口和越来越多的传染病和慢性病患者将推动对 ECMO 治疗的需求。 用于治疗成人患者的 ECMO 技术的进步也有望促进该行业的发展。
按地区划分,从 2023 年到 2032 年,拉丁美洲体外膜氧疗 (ECMO) 市场预计将以超过 4% 的复合年增长率增长。 这是由于尖端 ECMO 技术在拉丁美洲国家医疗机构中的使用迅速增加,以及该地区呼吸系统疾病和心脏病的发病率上升。 此外,该地区的扩张也将受益于受 COVID-19 影响的国家对 ECMO 设备需求的增加。
The global extracorporeal membrane oxygenation (ECMO) market is speculated to grow significantly through 2032 owing to increasing government initiatives as well as programs in Europe.
The prevalence of respiratory and cardiovascular illnesses has increased dramatically throughout the European region in recent years, and this trend is expected to continue over the forecast time. An increase in CVD cases has led to introduction of government measures and implementation of different programs in the area to raise public awareness. Government funding for infrastructure development in emerging nations would help make expensive machines more accessible, which will boost industry revenue growth.
For instance, in January 2021, Braile Biomedica, in collaboration with the Eldorado Institute and Embrapii, introduced the SOLIS System, a nationwide product against COVID-19. Extracorporeal membrane oxygenation (ECMO), a type of extracorporeal breathing, makes up the system. The corporation has benefited from such product introductions in securing its market position.
The ECMO market has been divided in terms of approach, type, patient population, and region.
Based on approach, the veno-venous (VV) segment held more than $180 million in 2022. The veno-venous ECMO device increases blood flow and oxygen levels while reducing cardiac effort and supporting hemodynamics. There will likely be a rise in demand for veno-venous ECMO through the forecast years due to the growing burden of cardiopulmonary diseases.
With respect to type, the respiratory segment is poised to grow at more than 3% CAGR from 2023 to 2032. A significant factor in the segment's growth is the risk of respiratory failure among individuals with different respiratory illnesses. Besides, the expanding geriatric population that is vulnerable to respiratory ailments, would further complement the growing market landscape.
In terms of the patient population, the adult segment is projected to foresee positive market expansion through the forecast years. The need for ECMO treatments will be driven by the growing elderly population base and the rise in the number of people with infectious and chronic diseases. Moreover, advancements in ECMO technology for treating adults is likely to contribute to the industry expansion.
From the regional front, the Latin America extracorporeal membrane oxygenation (ECMO) market is estimated to grow at more than 4% CAGR from 2023 to 2032. The expansion is fueled by the burgeoning use of cutting-edge ECMO technology in healthcare settings in LATAM nations along with the region's rising respiratory and cardiac disease rates. Additionally, the regional expansion will also benefit from the increased ECMO device demand in the COVID-19-affected nations.